Logo image of SLXN

SILEXION THERAPEUTICS CORP (SLXN) Stock Overview

NASDAQ:SLXN - KYG1281K1224 - Common Stock

7.26 USD
+0.06 (+0.83%)
Last: 8/27/2025, 8:18:08 PM
7.3003 USD
+0.04 (+0.56%)
After Hours: 8/27/2025, 8:18:08 PM

SLXN Key Statistics, Chart & Performance

Key Statistics
52 Week High193.73
52 Week Low6.51
Market Cap5.30M
Shares730.00K
Float720.00K
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-162.74
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO02-17 2021-02-17
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


SLXN short term performance overview.The bars show the price performance of SLXN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40

SLXN long term performance overview.The bars show the price performance of SLXN in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of SLXN is 7.26 USD. In the past month the price decreased by -35.87%. In the past year, price decreased by -96.32%.

SILEXION THERAPEUTICS CORP / SLXN Daily stock chart

SLXN Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.65 367.55B
AMGN AMGEN INC 13.2 155.03B
GILD GILEAD SCIENCES INC 14.72 141.35B
VRTX VERTEX PHARMACEUTICALS INC 22.97 99.76B
REGN REGENERON PHARMACEUTICALS 12.86 62.21B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.53B
ARGX ARGENX SE - ADR 76.37 43.33B
ONC BEONE MEDICINES LTD-ADR 6.06 35.68B
INSM INSMED INC N/A 28.44B
BNTX BIONTECH SE-ADR N/A 24.76B
NTRA NATERA INC N/A 22.38B
BIIB BIOGEN INC 8.52 19.99B

About SLXN

Company Profile

SLXN logo image Silexion Therapeutics Corp. engages in the discovery and development of treatments for KRAS-driven cancers. The firm is engaged in the development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a first-line treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.

Company Info

SILEXION THERAPEUTICS CORP

12 Abba Hillel Road

Ramat Gan IL

Employees: 11

SLXN Company Website

SLXN Investor Relations

Phone: 97286286005

SILEXION THERAPEUTICS CORP / SLXN FAQ

What is the stock price of SILEXION THERAPEUTICS CORP today?

The current stock price of SLXN is 7.26 USD. The price increased by 0.83% in the last trading session.


What is the ticker symbol for SILEXION THERAPEUTICS CORP stock?

The exchange symbol of SILEXION THERAPEUTICS CORP is SLXN and it is listed on the Nasdaq exchange.


On which exchange is SLXN stock listed?

SLXN stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for SILEXION THERAPEUTICS CORP stock?

7 analysts have analysed SLXN and the average price target is 24.48 USD. This implies a price increase of 237.19% is expected in the next year compared to the current price of 7.26. Check the SILEXION THERAPEUTICS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is SILEXION THERAPEUTICS CORP worth?

SILEXION THERAPEUTICS CORP (SLXN) has a market capitalization of 5.30M USD. This makes SLXN a Nano Cap stock.


How many employees does SILEXION THERAPEUTICS CORP have?

SILEXION THERAPEUTICS CORP (SLXN) currently has 11 employees.


What are the support and resistance levels for SILEXION THERAPEUTICS CORP (SLXN) stock?

SILEXION THERAPEUTICS CORP (SLXN) has a resistance level at 7.27. Check the full technical report for a detailed analysis of SLXN support and resistance levels.


Should I buy SILEXION THERAPEUTICS CORP (SLXN) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does SILEXION THERAPEUTICS CORP (SLXN) stock pay dividends?

SLXN does not pay a dividend.


What is the Price/Earnings (PE) ratio of SILEXION THERAPEUTICS CORP (SLXN)?

SILEXION THERAPEUTICS CORP (SLXN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-162.74).


SLXN Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

SLXN Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to SLXN. SLXN has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SLXN Financial Highlights

Over the last trailing twelve months SLXN reported a non-GAAP Earnings per Share(EPS) of -162.74. The EPS decreased by -4484.12% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -186%
ROE -597.55%
Debt/Equity 1.16
Chartmill High Growth Momentum
EPS Q2Q%-39.09%
Sales Q2Q%N/A
EPS 1Y (TTM)-4484.12%
Revenue 1Y (TTM)N/A

SLXN Forecast & Estimates

7 analysts have analysed SLXN and the average price target is 24.48 USD. This implies a price increase of 237.19% is expected in the next year compared to the current price of 7.26.


Analysts
Analysts82.86
Price Target24.48 (237.19%)
EPS Next Y92.88%
Revenue Next YearN/A

SLXN Ownership

Ownership
Inst Owners9.33%
Ins Owners0.64%
Short Float %N/A
Short Ratio0.05